Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02213744 · ClinicalTrials.gov registry record · Phase 2
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
A Phase 2 study, sponsored by Merrimack Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 113
- Enrollment target
NCT02213744: Clinical Trial Phase 2 study, sponsored by Merrimack Pharmaceuticals.
NCT02213744 is a Phase 2 study that was terminated before completion, run by Merrimack Pharmaceuticals. The registered enrollment target is 113 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (15% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02213744, a Phase 2 study, was terminated before completion, sponsored by Merrimack Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 113 participants
- Enrollment target
Study Summary
This study is an open label, randomized, multicenter trial of MM-302 plus trastuzumab. The trial is designed to demonstrate whether MM-302 plus trastuzumab is more effective than the chemotherapy of physician's choice (CPC) plus trastuzumab in locally advanced/metastatic HER2-positive breast cancer patients. Patients may not have been previously treated with an anthracycline in any setting. Patients must have received prior treatment with trastuzumab in any setting, have either progressed or are intolerant to ado-trastuzumab emtansine in the metastatic or locally advanced setting, have either progressed or are intolerant to pertuzumab in the metastatic or locally advanced setting or had disease recurrence within 12 months of pertuzumab treatment in the neoadjuvant or adjuvant setting.
Interventions
- DRUG Trastuzumab
- DRUG Capecitabine
- DRUG Gemcitabine
- DRUG Vinorelbine
- DRUG MM-302
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2014-07 |
| Est. Completion | 2017-06 |
| Phase | Phase 2 |
Why NCT02213744 stopped before completion
NCT02213744 is an interventional study that assigns participants to a tested intervention. The registered 113 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (15% lower).
The record links to 0 conditions, and to 5 interventions - of which Trastuzumab is the first listed.
NCT02213744 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02213744 about?
NCT02213744 is a clinical study titled "MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients". This study is an open label, randomized, multicenter trial of MM-302 plus trastuzumab. The trial is designed to demonstrate whether MM-302 plus trastuzumab is more effective than the chemotherapy of physician's choice (CPC) plus trastuzumab in locally advanced/metastatic HER2-positive breast cancer ...
What is the current status of trial NCT02213744?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 113 participants. The study started on 2014-07. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02213744?
The interventions under investigation include: Trastuzumab (DRUG), Capecitabine (DRUG), Gemcitabine (DRUG), Vinorelbine (DRUG), MM-302 (DRUG).
Who is sponsoring clinical trial NCT02213744?
This trial is sponsored by Merrimack Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02213744's enrollment target sits among peer trials
113 631st of 2000 higher than 1,370 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00748254 · 113 participants
Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis
- NCT04753190 · 113 participants · NA
Light Timing Study
- NCT05799248 · 113 participants · Phase 3
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
- NCT07216105 · 113 participants · Phase 1
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia